Financial Performance - Total revenue for the year ended December 31, 2023, was RMB 10,107,500, an increase of 28.0% from RMB 7,901,287 in 2022[2] - Profit attributable to equity holders of the parent company was RMB 257,680, a decrease of 3.3% from RMB 265,855 in 2022[2] - Basic and diluted earnings per share for 2023 were RMB 0.20, compared to RMB 0.21 in 2022[3] - Proposed final dividend per share increased to RMB 0.06 from RMB 0.03 in 2022[2] - Gross profit for the year was RMB 1,905,837, up 46.0% from RMB 1,305,835 in 2022[4] - Total comprehensive income for the year was RMB 313,584, down from RMB 329,887 in 2022[6] - The adjusted profit before tax for the group was RMB 492.92 million for the year ended December 31, 2023[17] - The company reported a pre-tax profit of RMB 4,477,328 thousand for 2023, compared to RMB 3,630,392 thousand in 2022, indicating an increase of approximately 23.3%[28] - The company reported a net profit of RMB 328,281,000 for the year, compared to RMB 328,281,000 in the previous year, indicating stable performance year-over-year[37] - The consolidated net profit for the reporting period was RMB 328 million, unchanged from the previous fiscal year, with earnings per share at RMB 0.20[41] Assets and Liabilities - Non-current assets totaled RMB 10,225,113, a decrease from RMB 11,051,287 in 2022[7] - Current assets decreased to RMB 3,429,079 from RMB 6,766,287 in 2022[7] - Total liabilities increased to RMB 6,641,126 from RMB 7,163,674 in 2022[8] - Net assets attributable to equity holders of the parent company decreased to RMB 5,811,794 from RMB 9,505,944 in 2022[8] - Total assets as of December 31, 2023, amounted to RMB 13,654,192 thousand, a decrease from RMB 17,817,574 thousand in the previous year[21] - Total liabilities stood at RMB 6,641,126 thousand, down from RMB 7,163,674 thousand as of December 31, 2022[21] - The total liabilities for the company were reported at RMB 1,731,495,000 in 2023, slightly down from RMB 1,734,297,000 in 2022, showing a marginal decrease of about 0.2%[34] - The total current liabilities reached RMB 5,124,310 thousand, with trade payables and notes payable at RMB 1,734,297 thousand[39] - The total non-current liabilities were RMB 2,039,364 thousand, with interest-bearing bank loans at RMB 1,017,263 thousand[39] - The group's total assets amounted to RMB 12,693,264 thousand, reflecting a strong asset base[39] Revenue Breakdown - Total revenue for the group was RMB 10.11 billion, with hospital business contributing RMB 9.41 billion and other businesses contributing RMB 702.25 million[18] - Hospital services generated RMB 5,473,459 thousand in revenue, up from RMB 4,084,293 thousand in 2022, reflecting a growth of about 34.0%[23] - Outpatient services revenue increased to RMB 3,932,694 thousand from RMB 2,968,853 thousand, marking a growth of approximately 32.5%[23] - The hospital business revenue reached RMB 9.41 billion, reflecting a 33.4% year-on-year growth from RMB 7.05 billion[47] - Outpatient service revenue was RMB 3.93 billion, up 32.5% year-on-year, while inpatient service revenue was RMB 5.47 billion, a 34.0% increase[49] Cost and Expenses - The group's total costs amounted to RMB 8.20 billion, with hospital business costs at RMB 7.67 billion and other business costs at RMB 530.35 million[18] - The total cost of goods sold for 2023 was RMB 4,477,328 thousand, up from RMB 3,630,392 thousand in 2022[28] - The company’s administrative expenses totaled RMB 710,424 thousand in 2023, compared to RMB 2,635,228 thousand in 2022, reflecting a significant increase in operational costs[28] - Administrative expenses totaled RMB 971 million, reflecting a year-on-year increase of 20.0%, but growth was controlled due to effective cost management[53] Goodwill and Impairment - The group recognized goodwill impairment losses of RMB 141.02 million during the reporting period[17] - The group faced a significant impairment loss of RMB 141 million related to goodwill and other assets, which reduced pre-tax profit by RMB 466 million[54] Dividends and Shareholder Returns - The company proposed a final dividend of RMB 0.06 per share for 2023, compared to RMB 0.037 per share in 2022, which is an increase of approximately 62.2%[30] - The ability to distribute dividends is contingent upon the group's financial condition, operational performance, liquidity, capital requirements, and any restrictions imposed by Cayman Islands law[69] Corporate Governance and Compliance - The company confirmed compliance with the corporate governance code during the fiscal year ending December 31, 2023, and will continue to review and meet shareholder expectations[72] - The audit committee, consisting of three independent non-executive directors, reviewed the financial reporting system and internal controls for the fiscal year ending December 31, 2023[73] - The external auditor, KPMG, confirmed that the financial data disclosed in the preliminary announcement aligns with the audited financial statements for the fiscal year ending December 31, 2023[74] Legal Matters - The Beijing High People's Court upheld the first-instance ruling regarding the YanHua IOT agreement, declaring the unilateral termination by YanHua Phoenix and YanHua Hospital invalid, and ordered YanHua Phoenix to pay RMB 14,400,000 in damages for breach of the agreement[75] - The company received RMB 14,400,000 in penalty payments from YanHua Phoenix through court enforcement in April 2022, following a lawsuit filed in January 2022[75] - The company initiated a new lawsuit in September 2022 against YanHua for additional damages incurred from 2019 to the time of the lawsuit, including management fees and supply chain costs[75] - The company will continue to take all appropriate actions to protect its interests and those of its shareholders regarding the YanHua IOT agreement dispute[75] Strategic Focus and Future Plans - The group has adopted new accounting policies in 2023, including IFRS 17 on insurance contracts, which may impact future financial reporting[12] - The group is evaluating the impact of new accounting standards that will take effect from January 1, 2024, but expects no significant impact on consolidated financial statements[15] - The group has adjusted its business unit structure, now reporting segments as hospital business and other services, reflecting changes in service offerings[16] - The company plans to enhance its core capabilities in discipline construction, patient services, and operational management to achieve better operational efficiency and economic benefits[66] - The company aims to deepen regional integration management and establish regional medical alliances to enhance management across various healthcare institutions[66] - The company will continue to strengthen its neurology specialty and expand its capabilities in the southern China region[66]

Acquisition and Consolidation - The company acquired 76.10% equity interests in Liaoning CR Healthcare and 100% equity interests in Shenzhen CR Healthcare, along with other assets, through cash settlements[9]. - The financial results of the newly acquired entities will be consolidated from January 1, 2023, and the comparative data for 2022 will be restated to include results from June 2, 2022[9]. - The acquisition includes sponsorship rights for 31 LH Member Institutions and six JE Member Medical Institutions, completed by the end of June 2023[9]. - The Group completed the acquisition of 76.10% of Liaoning China Resources Health and 100% of Shenzhen China Resources Health, among other transactions, by the end of June 2023[10]. - The equity transfers for the aforementioned transactions were completed by the end of June 2023, with financial results consolidated from June 2, 2022[53]. Financial Performance - The Group's consolidated revenue for the Reporting Period was RMB 5,114 million, a 59.5% increase from RMB 3,206 million in the corresponding period[10]. - The consolidated net profit for the Reporting Period was RMB 487 million, up 80.0% from RMB 271 million in the corresponding period[10]. - Earnings per share for the Reporting Period increased to RMB 0.31, compared to RMB 0.19 in the corresponding period[10]. - Revenue from LH Member Institutions and JE Member Medical Institutions contributed RMB 2,091 million to the consolidated revenue, while their net profit contribution was RMB 257 million[11]. - The Group's net profit for the reporting period was RMB 487 million, reflecting a significant year-on-year increase of 79.9%[44]. - Revenue for the six months ended June 30, 2023, was RMB 5,114,026, an increase of 59.5% from RMB 3,205,932 in the same period of 2022[143]. - Profit before tax increased to RMB 625,126, up 99.0% from RMB 313,961 in the prior year[143]. - Profit for the period was RMB 486,868, a 80.0% increase from RMB 270,596 in the previous year[145]. Operational Metrics - The number of conventional out-patient visits increased by 5.3% to approximately 7,100,000, and in-patient visits rose by 9.7% to approximately 310,000[13]. - Medical business revenue from member hospitals grew by 10.4% year-on-year[12]. - As of June 30, 2023, the Group managed a total of 146 medical institutions across 10 provinces and cities in China[13]. - The utilization rate of beds in self-owned hospitals was 80.60% during the Reporting Period[17]. - Total revenue from medical business for the Reporting Period was RMB 6,541 million, reflecting the combined performance of various medical institutions[17]. Expenses and Costs - The cost of sales and services for the first half of 2023 was RMB (4,024,751), compared to RMB (3,766,242) in 2022, indicating an increase of about 6.9%[21]. - Administrative expenses for the first half of 2023 were RMB (411,038), compared to RMB (396,023) in the same period of 2022, showing an increase of about 3.8%[21]. - Selling and distribution expenses increased to RMB (5,278) in the first half of 2023 from RMB (1,955) in 2022, indicating a significant rise[21]. - The finance costs remained stable at RMB (9,542) for the first half of 2023, unchanged from the previous year[21]. Cash Flow and Liquidity - The net cash flows from operating activities for the six months ended June 30, 2023, were RMB 540,437,000, compared to RMB 96,598,000 in the same period of 2022[156]. - The net cash flows from investing activities for the same period were RMB 398,705,000, significantly up from RMB 7,226,000 in 2022[156]. - The company reported a net increase in cash and cash equivalents of RMB 902,638,000, compared to RMB 59,537,000 in the previous year[158]. - Cash and cash equivalents at the end of the period stood at RMB 4,003,347,000, up from RMB 3,012,683,000 at the end of June 2022[158]. Employee and Staff Costs - As of June 30, 2023, the Group had a total of 20,189 full-time employees, a decrease from 20,622 employees as of December 31, 2022[75][78]. - For the reporting period, staff costs amounted to approximately RMB 1,667 million, compared to RMB 952 million in the corresponding period[75][78]. - The Group recognizes the importance of attracting and retaining qualified medical staff to ensure the sustainability of its operations[70]. Risk Management and Compliance - The Group's risk management and internal control systems are designed to protect assets and ensure compliance with relevant laws and regulations[91][92]. - The management closely monitors foreign exchange rate fluctuations to manage currency risk, without using any derivative contracts for hedging[72]. - The Board will continue to review and optimize the risk management and internal control systems in line with business development[93]. Share Capital and Dividends - The Group did not declare any interim dividend for the reporting period, consistent with the corresponding period[81][84]. - The share capital remained stable at RMB 267,000[149]. - The statutory surplus reserve was reported at RMB 228,546,000, unchanged from the previous period[153]. Future Strategies and Market Outlook - The Group aims to enhance its operational efficiency by integrating local healthcare systems and promoting the development of both leading hospitals and small to medium-sized hospitals[60]. - The medical service market in China is expected to maintain rapid growth due to an aging population and improved living standards[61]. - The company plans to continue expanding its market presence and enhancing its service offerings in the healthcare sector, focusing on both self-owned and third-party hospital collaborations[197].

Financial Performance - The revenue for the six months ended June 30, 2023, was RMB 5,114,026 thousand, an increase from RMB 3,205,932 thousand for the same period in 2022, representing a growth of approximately 59.5%[2] - Gross profit for the same period was RMB 1,089,275 thousand, compared to RMB 605,460 thousand in 2022, indicating a gross margin improvement[2] - The net profit attributable to equity holders of the parent company was RMB 244,669 thousand, up from RMB 270,596 thousand in the previous year, with basic and diluted earnings per share both at RMB 0.31[3] - The total segment profit for the six months ended June 30, 2023, was RMB 727,214 thousand, compared to RMB 378,269 thousand for the same period in 2022[12][13] - The company reported a pre-tax profit of RMB 625,126 thousand for the six months ended June 30, 2023[12] - The consolidated net profit for the reporting period was RMB 488 million, up from RMB 271 million in the same period last year, reflecting an increase of 80.4%[42] - The profit contribution from the self-owned hospital segment was RMB 646 million, reflecting a 131.8% increase compared to the previous year[54] - The group recorded a net profit of RMB 487 million, an increase of 79.9% year-on-year, with RMB 257 million contributed by the Liaojian and Jiangneng targets[60] Assets and Liabilities - Total non-current assets as of June 30, 2023, amounted to RMB 10,902,214 thousand, slightly down from RMB 11,051,287 thousand at the end of 2022[4] - Current assets increased to RMB 7,602,176 thousand from RMB 6,766,287 thousand, driven by an increase in trade receivables[4] - Total assets decreased to RMB 8,940,075 thousand from RMB 12,693,264 thousand, reflecting a significant reduction in total equity[5] - Total liabilities as of June 30, 2023, were RMB 11,325,340 thousand, including interest-bearing bank loans of RMB 2,434,037 thousand[15] - The total liabilities of the group amounted to RMB 7.163 billion, with current liabilities at RMB 5.124 billion[41] Cash Flow and Financial Management - The company reported a net current liability of RMB (1,962,139) thousand as of June 30, 2023, compared to a net current asset of RMB 1,641,977 thousand at the end of 2022[5] - The group has unutilized bank credit facilities of approximately HKD 2.93 billion and RMB 2.38 billion (approximately RMB 5.08 billion) as of June 30, 2023[7] - The board has reviewed the cash flow forecast for the next twelve months and believes that the group will have sufficient credit to repay its debts[7] - The company’s cash and cash equivalents, along with pledged deposits, totaled RMB 4,003,347 thousand as of June 30, 2023[15] - The company has a total credit facility of HKD 5.2 billion from overseas banks, with HKD 1.1 billion being a five-year committed loan and HKD 3 billion being a revolving credit facility[64] Operational Highlights - The company is primarily engaged in providing comprehensive medical services and hospital management services in mainland China[6] - The company managed and operated 146 medical institutions across 10 provinces and cities in China as of June 30, 2023[43] - The outpatient visits and inpatient admissions for the group’s member hospitals increased by 5.3% and 9.7% year-on-year, totaling approximately 7.1 million and 310,000 visits, respectively[43] - The total number of hospitals operated increased to 146, with a breakdown of 13 tertiary hospitals, 27 secondary hospitals, and 48 primary hospitals[44] - Inpatient services generated revenue of RMB 2,880,905 thousand, while outpatient services contributed RMB 1,863,619 thousand[20] Strategic Initiatives - The company aims to expand its market presence and enhance its service offerings through strategic initiatives in the healthcare sector[6] - The company plans to expand its market presence and enhance its service offerings through new product development and strategic acquisitions[48] - The group plans to enhance its capital structure and pursue mergers and acquisitions of quality hospitals to achieve its strategic goals during the 14th Five-Year Plan[63] - The company is focusing on market expansion and new product development, which are expected to drive future revenue growth and enhance competitive positioning[37] Accounting and Reporting - The group has adopted new accounting policies in 2023, including IFRS 17 on insurance contracts and amendments to IAS 1 and IAS 8, which did not have a significant impact on the financial statements[8] - The financial data is presented in RMB, rounded to the nearest thousand, and is based on historical cost conventions, except for certain financial assets measured at fair value[7] - The group applies the equity method for accounting for business combinations under common control, recognizing acquired assets and liabilities at their previous carrying amounts[9] - The group has not applied any new standards or interpretations that are not yet effective during the reporting period[8] Employee and Operational Challenges - Employee costs for the reporting period were approximately RMB 1.667 billion, compared to RMB 0.952 billion for the corresponding period[67] - The company employed a total of 20,189 full-time employees as of June 30, 2023, down from 20,622 employees as of December 31, 2022[67] - The company is facing talent shortages and is implementing measures to attract and retain qualified medical personnel to ensure the stability of its hospital operations[66] Governance and Compliance - The company is a limited liability company registered in the Cayman Islands on February 28, 2013[74] - The company is listed on the Hong Kong Stock Exchange[78] - The board of directors includes executive directors Song Qing, Yu Hai, Shan Baojie, and Yang Min, along with non-executive director Hu Hui and independent non-executive directors Hu Dingxu, Kuang Guoguang, and Fu Tingmei[80] - The announcement date is August 22, 2023, indicating recent developments in the company[80] - The company has no significant contingent liabilities or guarantees that would materially affect its financial position as of June 30, 2023[67]

[Supplemental Announcement to 2022 Annual Report](index=1&type=section&id=Further%20Information%20Regarding%20the%20Annual%20Report%20for%20the%20Year%20Ended%20December%2031%2C%202022) This announcement supplements the 2022 annual report, detailing valuation methods for goodwill and accounts receivable impairment [Explanation of Valuation Methodologies Adopted](index=1&type=section&id=Reasons%20for%20Adopting%20Certain%20Valuation%20Methodologies) This section clarifies valuation methods and rationale for goodwill and accounts receivable impairment at Huaiyin Hospital [Goodwill Impairment: Discounted Cash Flow Model](index=1&type=section&id=Provision%20for%20Goodwill%20Impairment%20%E2%80%94%20Discounted%20Cash%20Flow%20Model) The company assessed Huaiyin Hospital's goodwill impairment using the discounted cash flow model, aligning with IAS 36 - The company assessed goodwill impairment for Huaiyin Hospital using the income approach (discounted cash flow model), which complies with **International Accounting Standard 36 – Impairment of Assets**[1](index=1&type=chunk) - This method was adopted because Huaiyin Hospital has a long financial history, providing a reliable basis for forecasting future performance, thus its recoverable amount is valued based on the present value of future cash flows[1](index=1&type=chunk)[2](index=2&type=chunk) [Accounts Receivable Provision: Expected Credit Loss Model](index=2&type=section&id=Accounts%20Receivable%20Provision%20%E2%80%94%20Expected%20Credit%20Loss%20Model) The company assessed Huaiyin Hospital's accounts receivable impairment using the IFRS 9 expected credit loss model - Accounts receivable impairment assessment follows the requirements of **International Financial Reporting Standard 9 – Financial Instruments**, utilizing the expected credit loss model[3](index=3&type=chunk) - The company applies a simplified approach to calculate expected credit losses, recognizing loss allowances based on lifetime expected credit losses at each reporting date without tracking credit risk changes[3](index=3&type=chunk) - The company has established a provision matrix to calculate losses, based on past credit loss experience and adjusted for debtor-specific forward-looking factors and economic conditions[3](index=3&type=chunk)

Business Model and Strategy - In 2022, the company adjusted its business model from focusing on operational efficiency to a sustainable development model known as "1+X," aiming to enhance medical technology and create more value for public health[16]. - The new development model is expected to lead to high-quality and sustainable growth, with a focus on creating reasonable surpluses[16]. - The company is committed to strengthening supply chain management and financial resources to support its new business strategy[16]. - The Group aims to complete the acquisition of Liaojian and Jiangneng projects and focus on merging quality state-owned hospitals[25]. - The Group's strategy includes expanding its business scale and establishing an efficient regional medical system[25]. - The Group plans to enhance profitability by improving medical service quality and operational efficiency while focusing on core functions such as strategy and finance[102]. Financial Performance - The annual medical business income totaled RMB8.336 billion, representing a slight increase of 0.8% year-on-year[19]. - The net profit attributable to the owners of the parent was RMB139 million, a year-on-year decrease of 66.7% due to operating losses and impairments from the acquisition of Huaiyin Hospital[19]. - The Group recorded a net profit of RMB159 million, a decrease of 62.6% year-on-year, primarily due to operating losses and exchange losses[30]. - The Group's net profit for the Reporting Period was RMB159 million, representing a year-on-year decrease of approximately 62.6%[81]. - The Group's income tax expenses amounted to RMB83 million during the Reporting Period, compared to a credit figure of RMB155 million in FY2021[80]. - The Group's total staff cost for FY2022 was approximately RMB 1.78 billion, an increase from RMB 1.18 billion in FY2021, attributed to the consolidation of certain hospitals[130]. Operational Metrics - The Group's annual outpatient visits increased by 2.1% year-on-year, while inpatient visits rose by 1.5%[19]. - The Group managed and operated 116 medical institutions across 8 provinces, with annual outpatient visits reaching approximately 15.27 million, a 41.6% increase from 2021[32]. - The total number of patients treated in 2022 was 15,266,657, reflecting a significant operational scale[42]. - The total number of operational beds was 11,115 with an overall utilization rate of 73%[42]. - The number of outpatient visits reached 15,266,657, while inpatient visits totaled 286,152, contributing to a total medical business revenue of RMB 8,336,458,000[42]. Revenue Breakdown - Revenue from self-owned hospitals was RMB 5,178,404,000, while IOT/OT hospitals generated RMB 430,637,000 in revenue[48]. - The revenue from the self-owned hospital segment increased by 0.9% year-on-year to approximately RMB 6.76 billion, while segment results decreased by 14.7% to approximately RMB 437 million[55]. - The revenue from outpatient visits was RMB 4,158,753,000, and inpatient visits generated RMB 4,021,749,000[48]. - The revenue from general healthcare services increased significantly by 108.3% to RMB 287 million[60]. Challenges and Impairments - The Group experienced a 10% increase in the number of patients treated compared to the previous year[41]. - The Group did not have any significant investments accounting for 5% or more of total assets as of December 31, 2022[89]. - For the fiscal year ended December 31, 2022, the Company recorded a provision for goodwill impairment of approximately RMB108 million due to the gradual loss of medical staff at Huaiyin Hospital, which significantly impacted its operations[73]. - Huaiyin Hospital's medical business revenue dropped by more than 50% year-on-year in 2022, resulting in an operating loss of approximately RMB76 million[73]. Employee and Talent Management - The total number of full-time employees increased to 9,668 as of December 31, 2022, from 8,454 in the previous year[130]. - Employee costs for the fiscal year 2022 amounted to approximately RMB 1.78 billion, up from RMB 1.18 billion in the fiscal year 2021, attributed to the consolidation of several hospitals during the year[133]. - The Group is committed to providing a safe and harassment-free working environment for employees, emphasizing workplace safety throughout the year[165]. - The Group has implemented a talent attraction program in response to the attrition of medical staff at Huaiyin Hospital to improve operations[73]. Environmental and Governance Policies - The Group has implemented environmental policies in compliance with PRC laws, with no material environmental claims or penalties reported during the year ended December 31, 2022[151]. - The Group has established a "Hazardous Substances Safety Management Plan" and a "Medical Waste Management System" for all hospitals to manage hazardous materials and medical waste[152]. - The Group's environmental, social, and governance report will be published alongside the annual report, detailing measures taken in these areas[160]. Dividends and Shareholder Information - The Group proposes a 2022 Final Dividend of 3.7 HK cents per Share, down from 12 HK cents in FY2021, totaling approximately HK$48 million[171]. - The Group's ability to pay dividends is contingent on its financial condition, operations, liquidity, and capital requirements[174]. - The company has no assurance that dividends will be paid in any particular amount for any given period[179].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Resources Medical Holdings Company Limited 華潤醫療控股有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 截至2022年12月31日止年度全年業績公告 | --- | --- | --- | |--------------------------------------------------|-----------|-----------| | | | | | 財務摘要 | 2022 年 | 2021 年 | | | | | | 收益（人民幣千元） | 5,620,461 | 4,447,477 | | 母公司擁有人應佔年度利潤（人民幣千元） | 138,974 | 417,915 | | 母公司普通股權益持有人應佔每股盈利（基本及攤薄） | | | | （人民幣） | 0.11 | 0.33 | | 建議分派之每股末期股息（港 ...

Financial Performance - The consolidated revenue for the reporting period amounted to RMB 2,850 million, a year-on-year increase of 60.8% from RMB 1,772 million[12]. - Net profit for the reporting period was RMB 215 million, slightly up from RMB 205 million in the corresponding period, indicating stable growth[12]. - Earnings per share remained unchanged at RMB 0.16 compared to the previous period[12]. - Total revenue from medical business for H1 2022 reached RMB 4,017,215, an increase from RMB 3,287,449 in the corresponding period[22]. - The net profit for H1 2022 was RMB 214,747, compared to a loss of RMB 5,740 in the corresponding period[22]. - The Group recorded a net profit of RMB 215 million, representing a year-on-year increase of 4.6%[41]. - Revenue for the six months ended June 30, 2022, was RMB 2,850,489, an increase of 61% compared to RMB 1,772,123 for the same period in 2021[118]. - Gross profit for the same period was RMB 524,266, representing a gross margin of approximately 18.4%[118]. - Profit before tax for the six months ended June 30, 2022, was RMB 254,175, a decrease of 5.9% from RMB 270,142 in the prior year[118]. - Comprehensive income for the period was RMB 214,747, compared to RMB 205,325 for the same period in 2021, indicating a slight increase[118]. Operational Metrics - The total number of outpatient visits increased by 66.1% to approximately 7.87 million, while inpatient visits rose by 11.4% to around 143,000[15]. - The number of operational beds increased to 11,369 with an overall utilization rate of 70.7%[19]. - Out-patient visits totaled 7,869,968, while in-patient visits were 142,877 for H1 2022[19]. - Total number of patients treated in H1 2022 was 7,869,968, with 4,941,511 being out-patients[19]. - The utilization rate of self-owned hospitals was 73.7%, while IOT/OT hospitals had a utilization rate of 51.6%[19]. Revenue Breakdown - Revenue from out-patient visits was RMB 1,996,751, and revenue from in-patient visits was RMB 1,971,362[22]. - Total revenue from medical business for self-owned hospitals increased by 7.7% year-on-year to approximately RMB 3.29 billion[29]. - The segment results for self-owned hospitals recorded a decrease of 1.7% to approximately RMB 265 million[31]. - IOT/OT hospitals segment achieved a 0.9% increase in medical business revenue, totaling RMB 729,766[34]. - IOT/OT hospitals segment results increased by 19.2% to RMB 58,843[34]. - Revenue from general healthcare services and hospital management services increased by 46.6% to RMB 121,373[32]. Expenses and Costs - The company reported administrative expenses of RMB 256,204, an increase from RMB 237,078 in the previous period[22]. - Total operating expenses of the headquarters decreased to approximately RMB 36 million, accounting for 12.4% of total administrative expenses[35]. - Staff costs for the reporting period were approximately RMB 836 million, a significant increase from RMB 471 million in the corresponding period[63]. - Selling and distribution expenses were RMB 8,779, while administrative expenses totaled RMB 292,473, indicating an increase in operational costs[118]. - The Group's profit before tax for the six months ended 30 June 2022 was significantly impacted by a cost of inventories sold amounting to RMB 1,476,492, an increase of 59.7% compared to RMB 924,993 in 2021[198]. Assets and Liabilities - The total assets as of June 30, 2022, were reported at RMB 5,000,000, compared to RMB 4,500,000 as of December 31, 2021, showing a growth in asset base[119]. - Total non-current assets increased to RMB 6,708,546, up from RMB 6,543,020, representing a growth of approximately 2.52%[120]. - Current assets rose to RMB 4,154,816, compared to RMB 3,924,582, reflecting an increase of about 5.86%[120]. - Total non-current liabilities surged to RMB 1,123,016, compared to RMB 177,423, indicating a dramatic rise[122]. - Total liabilities as of June 30, 2022, amounted to RMB 3,621,157, with interest-bearing bank borrowings at RMB 1,646,624[178]. Strategic Initiatives - The Group's strategic expansion includes the consolidation of additional medical institutions into its operations, enhancing its market presence[13]. - Future plans include enhancing the "RUNXIN" patient service system and modernizing hospital operations to improve service quality[53]. - The Group aims to improve operational efficiency and medical service quality through policy research on medical insurance payment reform and timely measures[55]. - The Group plans to seize merger and acquisition opportunities during the state-owned hospital reform period to accelerate growth[55]. - The Group recognizes the importance of maintaining relationships with patients and partners for sustainable development[62]. Governance and Compliance - The Company confirmed compliance with all material code provisions of the Corporate Governance Code during the reporting period[71]. - The risk management and internal control systems are designed to protect the Group's assets and ensure compliance with relevant laws and regulations[74]. - The Board will continue to optimize risk management and internal control systems in line with business development[80]. - The Group has performed annual impairment reviews of sponsorship rights, service contracts, and goodwill, concluding no impairment was required as of June 30, 2022[85]. Shareholder Information - China Resources Company Limited holds 474,319,516 shares, representing approximately 36.58% of the total issued shares[104]. - Mitsubishi UFJ Financial Group, Inc. holds 77,645,666 shares, accounting for about 5.98% of the total issued shares[104]. - The Board did not recommend the payment of any interim dividend for the reporting period, consistent with the corresponding period[68]. - No share options were granted, exercised, cancelled, or lapsed during the reporting period, and there are no outstanding share options under the Share Option Scheme[89].

Financial Performance - The Group recorded a net profit attributable to the parent of RMB418 million, an increase of 34.8% year-on-year and 6.9% compared to 2019[15]. - Total medical business revenue was RMB8,272 million, representing a rise of 24.5% year-on-year and a 20.4% increase compared to 2019[15]. - The Group achieved a consolidated revenue of RMB 4,447 million for the year ended December 31, 2021, representing a 61.6% increase from RMB 2,751 million in 2020 and a 109.8% increase from RMB 2,115 million in 2019[31]. - The net profit for the Group was RMB 426 million in 2021, up 33.1% from RMB 320 million in 2020 and a slight increase of 6.2% from RMB 401 million in 2019[32]. - The Group recorded a net profit of RMB 426,000,000 in 2021, representing a year-on-year increase of approximately 33%[95]. - The Group's earnings per share increased to RMB 0.33 in 2021, up from RMB 0.25 in 2020 and RMB 0.31 in 2019[32]. Operational Metrics - In 2021, the number of outpatient visits to member hospitals increased by 39.9% year-on-year and by 22.8% compared to 2019[15]. - The number of inpatient visits grew by 28.3% year-on-year and by 11.7% compared to 2019[15]. - The outpatient volume of member hospitals increased by 39.9% year-on-year and by 22.8% compared to 2019, while inpatient volume grew by 28.3% year-on-year and by 11.7% compared to 2019[17]. - The annual number of inpatient visits was approximately 282,000, reflecting an increase of 28.3% compared to 2020[37]. - The Group's member hospitals have shown a consistent trend of increasing operational metrics, indicating a positive outlook for future performance[40]. Strategic Initiatives - The company aims to be a leading healthcare group in China and a pioneer in the reform of state-owned medical institutions as part of its 14th Five-Year strategic plan[13]. - The Group aims to establish regional leading hospital clusters and academic specialty hospital clusters during the 14th Five-Year Plan, focusing on organic growth and external expansion[25]. - The Group plans to enhance medical technology, quality, and service capabilities to achieve high-quality growth and boost commercial value through group management and efficiency improvements[26]. - The company expressed gratitude to shareholders, staff, and frontline medical workers for their support during the pandemic[14]. Acquisitions and Consolidations - The Group consolidated the financial statements of Guangdong 999 Brain Hospital and Xukuang Hospital starting from August 2021, enhancing the reflection of business performance in financial statements[24]. - The acquisition of Huaiyin Hospital, a Grade II comprehensive for-profit hospital, was completed in June 2021, further expanding the Group's presence in the Yangtze River Delta region[20]. - The Group completed the acquisition of Huaiyin Hospital, which has been consolidated into the Group's financial statements since June 2021[38]. - The acquisitions of Jinan Zhongqi Hospital and Huaiyin Hospital contributed to the revenue growth in the self-owned hospitals segment[76]. Employee and Operational Management - As of December 31, 2021, the Group had a total of 8,454 full-time employees, an increase from 4,903 employees as of December 31, 2020[133]. - For FY2021, the staff cost was approximately RMB 1.18 billion, up from RMB 685 million in FY2020, primarily due to the acquisition and consolidation of certain hospitals[133]. - The Group has taken measures to attract, train, and retain qualified medical personnel to mitigate talent risk[130]. - The Group emphasizes the importance of relationships with patients and partners for sustainable business development[130]. Financial Position and Investments - As of December 31, 2021, the Group's consolidated bank balances and cash amounted to approximately RMB 3.23 billion, an increase from RMB 3.09 billion as of December 31, 2020[115]. - The Group's interest-bearing bank borrowings totaled approximately RMB 1.65 billion as of December 31, 2021, compared to approximately RMB 684 million as of December 31, 2020, indicating a significant increase[116]. - The Group's gearing ratio was 15.9% as of December 31, 2021, up from 7.6% as of December 31, 2020, reflecting increased leverage[117]. - The Group's investment in joint ventures and associates contributed a profit of RMB 83,553,000 during the reporting period[68]. Corporate Social Responsibility and Compliance - The Group has implemented strict environmental policies and complied with all relevant PRC laws regarding environmental protection during the year[151]. - The Group has developed various safety management plans, including the "Hazardous Substances Safety Management Plan" and "Medical Waste Management System" to ensure compliance with environmental regulations[152]. - The Group considers its employees as key to sustainable business growth and maintains a high standard of health and safety measures[165]. - The Group emphasizes a commitment to employee safety and equal opportunities, integrating these principles into its corporate responsibility policies[168]. Dividend and Shareholder Information - The Group proposes a final dividend of 12 HK cents per share for FY2021, an increase from 8.82 HK cents in FY2020, totaling approximately HK$156 million[171][175]. - The Group's ability to pay dividends is subject to its financial condition, operations, liquidity, and capital requirements[174][177]. - As of December 31, 2021, the Company's share premium amounted to RMB5,785,472,000, down from RMB5,877,796,000 in 2020, available for distribution to shareholders[183][189].

Financial Performance - The consolidated revenue for the six months ended June 30, 2021, amounted to RMB 1,772 million, a 95.2% increase from RMB 907 million in the same period last year[8]. - Net profit for the period was RMB 205 million, up 86.4% from RMB 110 million in the same period last year[8]. - Earnings per share increased to RMB 0.16, compared to RMB 0.09 in the same period last year[8]. - The total revenue from medical business for the first half of 2021 was RMB 3,777.148 million, with RMB 1,138.886 million from consolidated hospitals, RMB 1,914.703 million from unconsolidated hospitals, and RMB 723.559 million from IOT/OT hospitals[18]. - The group reported a net profit of RMB 205.325 million for the first half of 2021, with administrative expenses amounting to RMB 127.506 million[18]. - The financial results demonstrate a robust growth trajectory in the medical business, highlighting the effectiveness of the group’s expansion strategies[18]. - The effective control of the COVID-19 epidemic has led to a satisfactory recovery of operations and growth in revenue across the Group's member medical institutions[25]. - The Group recorded a net profit of RMB 205 million, representing an increase of 86.3% year-on-year[42]. - The company reported a significant increase in other income, which rose to RMB 54,697 from RMB 38,779, indicating improved operational efficiency[126]. - The company reported a fair value loss on financial assets at FVTPL of RMB 21,876,000, impacting overall profitability[167]. Operational Metrics - The overall number of out-patients and in-patients increased by 50.5% and 36.8%, respectively[8]. - The group operated 11,097 beds with an overall bed utilization rate of 71.6% during the first half of 2021, accommodating 128,270 inpatients[14][18]. - The revenue from outpatient visits was RMB 1,784.523 million, while inpatient visits generated RMB 1,928.301 million in revenue during the same period[18]. - The group’s outpatient and inpatient visit numbers reflect a significant operational scale, indicating strong demand for healthcare services[12][13]. - The segment results for unconsolidated hospitals showed a profit of RMB 154,745,000, indicating healthy operational performance[167]. Acquisitions and Expansions - On March 28, 2021, the company agreed to acquire approximately 99.19% of Huaiyin Hospital for a consideration of approximately RMB 880 million[9]. - The acquisition of Huaiyin Hospital was completed on June 17, 2021, and its financial statements have been consolidated into the Group[9]. - Jianghua Management Limited acquired 99.19% of Sinophi China Hospitals Limited for approximately RMB 880 million, completing the acquisition on June 17, 2021[11]. - The acquisition of Huaiyin Hospital indirectly increased the group’s operational capacity, as the hospital has approximately 1,190 open beds[11]. - The Group aims to enhance its core medical services and develop six discipline clusters, including cardiovascular and oncology, to strengthen its brand in these areas[55][57]. Financial Position - As of June 30, 2021, the group managed a total of 123 medical institutions across 8 provinces and cities in China, with approximately 4.739 million outpatient visits and 128,000 inpatient visits during the reporting period[12][13]. - As of June 30, 2021, the Group's consolidated bank balances and cash amounted to approximately RMB 2.49 billion, down from approximately RMB 3.09 billion as of December 31, 2020[60]. - The Group's gearing ratio as of June 30, 2021, was 16.3%, an increase from 7.6% as of December 31, 2020[61]. - Total non-current assets as of June 30, 2021, amounted to RMB 6,519,806, an increase from RMB 4,816,301 as of December 31, 2020[130]. - Total current assets were RMB 3,806,706, down from RMB 4,146,892 at the end of 2020, indicating a decrease in liquidity[130]. - Net current assets decreased to RMB 566,964 from RMB 1,939,706, highlighting a potential liquidity concern[130]. - Total liabilities were reported at RMB 3,705,924,000, including interest-bearing bank borrowings of RMB 1,663,511,000[177]. Staff and Management - As of June 30, 2021, the Group had a total of 6,097 full-time employees, an increase from 4,903 employees as of December 31, 2020, primarily due to the acquisition of Huaiyin Hospital[67]. - Staff costs for the six months ended June 30, 2021, were approximately RMB 471 million, compared to RMB 205 million for the same period in 2020, reflecting a significant increase[67]. - The Board did not recommend the payment of any interim dividend for the six months ended June 30, 2021, consistent with the previous year[71]. Risk Management and Compliance - The Group's risk management and internal control systems are designed to protect assets and ensure compliance with laws and regulations[82]. - The Audit Committee reviewed the unaudited consolidated interim results and confirmed compliance with relevant accounting standards and legal requirements[77]. - The Company confirmed compliance with all material code provisions of the Corporate Governance Code during the reporting period[75]. Future Strategies - The Group plans to improve operational efficiency and reduce costs while expanding existing hospitals and pursuing mergers and acquisitions[55][57]. - Future strategies include enhancing operational efficiencies and exploring potential acquisitions to strengthen market position[170].

Financial Performance - In 2020, the total medical business revenue was RMB 6.644 billion, representing a slight decrease of 3.3% from the previous year[13]. - The consolidated net profit for 2020 was RMB 320 million, a 20% decrease from the previous year[13]. - The consolidated revenue for the year ended December 31, 2020, was RMB 2.751 billion, an increase from RMB 2.115 billion in FY2019, primarily due to the acquisition of Jinan Zhong Qi Hospital[25]. - Net profit for the period was RMB 320 million, down from RMB 401 million in FY2019, with earnings per share decreasing to RMB 0.25 from RMB 0.31, mainly due to a drop in hospital visits caused by the COVID-19 epidemic[25]. - The total revenue from medical business of member hospitals was approximately RMB 6.644 billion, representing a year-over-year decrease of 3.3% due to the impact of the COVID-19 epidemic[26]. - The Group recorded a net profit of RMB320 million, representing a year-on-year decrease of approximately 20.0% due to the impact of the COVID-19 epidemic[78]. - The total revenue from goods and services for the reporting period was approximately RMB2.751 billion, with a cost of sales amounting to RMB2.114 billion, resulting in a gross profit of RMB636 million[48]. - The segment results for 2020 amounted to approximately RMB452 million, representing a decrease of about 31.7% compared to the previous year, primarily due to a 12.9% decrease in inpatient visits and a 12.2% decrease in outpatient visits attributed to the COVID-19 epidemic[51][52]. - Revenue from the consolidated hospital segment increased by 127.9% year-on-year to approximately RMB1.644 billion, with segment results rising by 2.9% to approximately RMB128 million, driven by the recovery of operations in the Huaikuang Hospital Group and Jinan Zhong Qi Hospital[55]. - The unconsolidated hospital segment experienced a medical business revenue decline of 32.6% year-on-year to approximately RMB 2.344 billion, with a profit decrease of 45.7% to approximately RMB 131 million[63]. Operational Developments - The company completed the acquisition of Jinan Zhong Qi Hospital in early 2020 and acquired the remaining equity interest in the second half of the year[16]. - The company formed a neurology specialty cluster centered around Sanjiu Brain Hospital, consolidating medical resources in Guangdong and Guangxi[16]. - The company focused on enhancing six main discipline clusters: orthopedic, encephalopathy, rehabilitation, oncology, cardiology, and gastroenterology through new talents and technologies[16]. - Business operations began to significantly recover from May 2020, with a rebound in patient numbers observed[32]. - The management team implemented a phased resumption of operations, with all member hospitals returning to normal operations by the end of March 2020[32]. - The Group completed the acquisition of Jinan Zhong Qi Hospital and consolidated certain other hospitals, with the financial statements of Jinan Zhong Qi Hospital being included in the Group's financials since April 2020[33]. - The Group has consolidated additional hospitals into its financial results, enhancing its operational capacity and market presence[54][56]. - The Group's financial statements have included Run Neng Hospitals since June 2020 following similar constitutional amendments[34]. - The Group has established a strong supply chain management system to ensure sufficient medical supplies during the COVID-19 epidemic[30]. Human Resources - As of December 31, 2020, the Group had a total of 4,903 full-time employees, a significant increase from 1,178 employees as of December 31, 2019[124]. - For FY2020, the staff cost was approximately RMB 685 million, up from RMB 355 million in FY2019, primarily due to acquisitions and consolidations of hospitals[124]. - The Group is actively working to attract and retain qualified medical staff to mitigate the risk of talent shortage[109][114]. Strategic Focus - The company aims to focus on business development in key regions including Beijing-Tianjin-Hebei, the Yangtze River Delta, and the Greater Bay Area[19]. - The company plans to strengthen key specialties and accelerate the transformation of specialty clusters to enhance its clinical brand and service quality[21]. - Future plans include focusing on specialty chain hospitals and general hospitals, with a geographical focus on key regions in China[95]. - The Group aims to cultivate six discipline clusters in cardiovascular, encephalopathy, orthopedics, rehabilitation, gastroenterology, and oncology to strengthen competitive advantages[95]. Financial Management - The Group's liquidity and financing strategy emphasizes maintaining a solid financial position through cash generated from operations and bank facilities[96]. - As of December 31, 2020, the Group's consolidated bank balances and cash amounted to approximately RMB 3.09 billion, an increase from approximately RMB 2.276 billion as of December 31, 2019[100][104]. - The Group has obtained offshore revolving term loan facilities totaling HK$3.8 billion, with HK$3 billion having no fixed term and HK$800 million being a one-year term[101][105]. - Interest-bearing bank borrowings as of December 31, 2020, were HK$799 million and RMB 12 million, equivalent to approximately RMB 684 million, compared to HK$646 million (approximately RMB 578 million) as of December 31, 2019[101][105]. - The Group's gearing ratio was 7.6% as of December 31, 2020, slightly up from 7.3% as of December 31, 2019[102][106]. - The Group's unutilized bank facilities amounted to HK$3.001 billion and RMB 3 million, equivalent to approximately RMB 2.529 billion as of December 31, 2020[101][105]. Corporate Governance and Compliance - The Group has complied with all relevant PRC laws and regulations regarding environmental protection during the year ended December 31, 2020[144]. - The Group has implemented various safety management plans, including those for hazardous substances and medical waste, to ensure compliance with environmental laws[145]. - The Group emphasizes the importance of employee welfare, providing a safe working environment and equal opportunities for career development[158]. - The Group's sustainability report will be published within three months after the annual report, detailing environmental, social, and governance measures[149]. - The Group maintains a fair and effective performance appraisal system and incentive bonus schemes to motivate employees[158]. - The Group is committed to balancing the interests of various stakeholders, including substantial shareholders, employees, and the community[151]. Dividends and Shareholder Returns - The Group proposes a final dividend of 8.82 HK cents per share for FY2020, down from 10 HK cents in FY2019, totaling approximately HK$114 million[164]. - The Group's ability to pay dividends is subject to its financial condition, operations, liquidity, and capital requirements[167]. - The dividend policy will be reviewed periodically, with no assurance of specific amounts being paid in any given period[172].